

## Myeloma and Related Disorders

### Activity Description

Mayo Clinic faculty presenting didactic and interactive sessions addressing issues related to plasma cell disorders.

### Target Audience

This online course is designed for Medical Oncologists, Radiation Oncologists, Surgical Oncologists and Oncology nurses involved in cancer care.

### Learning Objectives

- Interpret new, practice-relevant data in diagnosing and risk stratifying monoclonal plasm cell disorders.
- Integrate evidence-based treatment strategies into clinical practice for monoclonal gammopathies.
- Integrate supportive care approaches into treatment of myeloma.

### Accreditation Statement



In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team

### Credit Statement

#### AMA

The Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 13.25 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Disclosure Summary

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed...

#### *Relevant financial relationship(s) with industry:*

---

| <u>Name</u>               | <u>Nature of Relationship</u>        | <u>Company</u>   |
|---------------------------|--------------------------------------|--|
| Sikander Ailawadhi, M.D.  | Consultant<br>Grant/Research Support | Celgene, Takeda, Novartis, Amgen<br>Pharmacyclics, Inc.  |
| David Dingli, M.D., Ph.D. | Honoraria                            | Millenium/Takeda, Alexion, Rigel   |
| Angela Dispenzieri, M.D.  | Grant/Research Support               | Takeda, Pfizer, Prothena, Celgene, Alnylam, Janssen  |
| Rafael Fonseca, M.D.      | Consultant/Other                     | Amgen, BMS, Celgene, Takeda, Nayer, Janssen,<br>Novartis, Pharmacyclics, Sanofi, Merck, Juno, Kite,<br>Aduro, AbbVie, Adaptive Biotechnologies |
| Morie A. Gertz, M.D.      | Honoraria                            | Lonis, Alnylym, Prothena, Celgene, Janssen,<br>Spectrum, Annexon, Appellis, Amgen, Medscape,   |

Physicians Education Resource, Abbvie, Research to Practice, Teva, Dava Oncology, Johnson and Johnson

Yi (Yi Lisa) L. Hwa, APRN Honoraria  
C.N.P., D.N.P.

NCCN

Prashant Kapoor, M.D. Grant/Research Support

Amgen, Takeda, and Sanofi

Shaji Kumar, M.D. Consultant  
Grant/Research Support  
Honoraria

Celgene, Takeda, Janssen, KITE, Merck, Abbvie, Medimmune, Genentech, Oncoceptides, Amgen  
Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen  
Prothena, Oncoceptides

Nelson Leung, M.D. Consultant  
Grant/Research Support

Takeda, Prothena, BTG  
Omeros Corporation

David Murray, M.D., Ph.D. Grant/Research Support  
Other

The Binding Site  
Intellectual Property Royalties related to mass spec detection of plasma cell disorders  
Amgen, Bristol Myers-Squibb, Celgene, Ionis, Janssen, Oncoceptides, Ono, Roche, Seattle Genetics, Takeda

Keith Stewart, M.B., Ch.B.. Consultant

***No relevant financial relationship(s) with industry:***

**Name**

Victoria R. Alegria, APRN  
Linda B. Baughn, Ph.D.  
Francis K. Buadi, M.D.  
Matthew T. Drake, M.D., Ph.D.  
Nicole A. Gannon, P.A.-C.  
Wilson I. Gonsalves, M.D.  
Dragan Jevremovic, M.D., Ph.D.  
Robert A. Kyle, M.D.  
Jeremy T. Larsen, M.D.  
Yi Lin, M.D., Ph.D.  
John A. Lust, M.D., Ph.D.  
Kristen B. McCullough, Pharm.D., R.Ph.  
S. Vincent Rajkumar, M.D.

***References to off-label and/or investigational usage(s) of pharmaceuticals or instruments in their presentation:***

| Name                                   | Manufacturer/Provider             | Product/Device   |
|--|-----------------------------------|--|
| Prashant Kapoor, M.D.                  | IVIG, Selinexor                   | Karyopharm   |
| Nelson Leung, M.D.                     | Takeda                            | Bortezomib   |
| John A. Lust, M.D., Ph.D.              | Celegene                          | Revlimid,  |
| Kristen B. McCullough, Pharm.D., R.Ph. | Pfizer, Mylan, Eli Lilly, Janssen | Gabapentin, amitriptyline (no longer made in US), Duloxetine, subcutaneous daratumumab, pregabalin, venlafaxine, |

**Mayo Disclaimer**

Participation in this Mayo Clinic educational activity does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course. You should be aware that substantive developments in the medical field covered by this recording may have occurred since the date of original release.

**Prerequisites for Participation**

There are no prerequisites needed prior to participating in this education activity.

**How to Obtain Credit**

To obtain credit, complete the post-test, evaluation and submit.

**Method of Participation**

Participation in this activity consists of reviewing the online lectures and completing the post-test and evaluation.

**Release and Expiration Dates**

Release Date: September 15, 2018

Original Expiration Date: January 15, 2020

Expiration Date: January 15, 2023

**Acknowledgement of Commercial Support**

No commercial support was received in the production of this activity.

**Faculty and Course Director Listing and Credentials****Course Director**

Shaji Kumar, M.D.

**Mayo Clinic Faculty**

Sikander Ailawadhi, M.D.

Victoria R. Alegria, APRN

Linda B. Baughn, Ph.D.

Francis K. Buadi, M.D.

David Dingli, M.D., Ph.D.

Angela Dispenzieri, M.D.

Matthew T. Drake, M.D., Ph.D.

Rafael Fonseca, M.D.

Nichole A. Gannon, P.A.-C.

Morie A. Gertz, M.D.

Wilson I. Gonsalves, M.D.

Yi (Yi Lisa) L. Hwa, APRN, C.N.P., D.N.P.

Dragan Jevremovic, M.D., Ph.D.

Prashant Kapoor, M.D.

Shaji Kumar, M.D.

Robert A. Kyle, M.D.

Jeremy T. Larsen, M.D.

Nelson Leung, M.D.

Yi Lin, M.D., Ph.D.

John A. Lust, M.D., Ph.D.

Kristen B. McCullough, Pharm.D., R.Ph.

David L. Murray, M.D., Ph.D.

S. Vincent Rajkumar, M.D.

Keith Stewart, M.B., Ch.B.

| <b>Course Program and Faculty</b>  | <b>Run Time</b> |
|--|-----------------|
| History of Myeloma and Monoclonal Gammopathies<br><i>Robert A. Kyle, M.D.</i>  | 27:14           |
| Monoclonal Gammopathies: Diagnostic Considerations<br><i>S. Vincent Rajkumar, M.D.</i>                                 | 38:16           |
| Initial Workup of Myeloma: Pathological Considerations<br><i>Dragan Jevremovic, M.D., Ph.D.</i>                        | 30:34           |
| Monoclonal Protein Testing<br><i>David L. Murray, M.D., Ph.D.</i>  | 35:45           |
| Cytogenetics and FISH Studies<br><i>Linda B. Baughn, Ph.D.</i>   | 33:21           |
| Multiple Myeloma: Risk Stratification<br><i>Prashant Kapoor, M.D.</i>  | 39:15           |
| Smoldering Myeloma: Current Approaches<br><i>John A. Lust, M.D., Ph.D.</i>   | 31:51           |
| Response Assessment in Plasma Cell Disorders<br><i>Shaji Kumar, M.D.</i>   | 26:48           |
| Assessment of Myeloma Bone Disease<br><i>Matthew T. Drake, M.D., Ph.D.</i>   | 37:44           |
| Initial Therapy of Myeloma: Transplant-Eligible Patients<br><i>Shaji Kumar, M.D.</i>                                   | 24:06           |
| Role of Stem Cell Transplantation in Myeloma<br><i>Morie A. Gertz, M.D.</i>  | 35:44           |
| Initial Therapy of Myeloma: Transplant-Ineligible Patients<br><i>Shaji Kumar, M.D.</i>                                 | 22:26           |
| Post-Transplant Approaches in Myeloma<br><i>Francis K. Buadi, M.D.</i>   | 41:51           |
| Treatment Approaches for Relapsed Myeloma<br><i>David Dingli, M.D., Ph.D.</i>  | 47:18           |
| Management of Waldenstrom Macroglobulinemia<br><i>Prashant Kapoor, M.D.</i>  | 55:43           |
| Monoclonal Gammopathies and the Kidney<br><i>Nelson Leung, M.D.</i>  | 44:34           |
| Light Chain Amyloidosis: Diagnosis and Treatment<br><i>Angela Dispenzieri, M.D.</i>                                    | 57:42           |
| Supportive Care in Myeloma<br><i>Morie A. Gertz, M.D.</i>  | 39:08           |
| Counseling Myeloma Patients Regarding Therapy: Tips from a Pharmacist<br><i>Kristen B. McCullough, Pharm.D., R.Ph.</i> | 23:36           |
| Monoclonal Antibodies and CAR T-cell Therapy in Myeloma: Current Status<br><i>Yi Lin, M.D., Ph.D.</i>                  | 43:40           |
| Emerging Novel Drugs in Myeloma<br><i>Shaji Kumar, M.D.</i>  | 19:49           |
| Uncommon Plasma Cell Disorders<br><i>Prashant Kapoor, M.D.</i>   | 52:59           |

| <b>Bonus Instructional Hours and Faculty</b>  | <b>Run Time</b> |
|---|-----------------|
| POEMS Syndrome ( <i>audio only</i> )<br><i>Angela Dispenzieri, M.D.</i>   | 24:16           |
| Plasma Cell Leukemia ( <i>audio only</i> )<br><i>Wilson I. Gonsalves, M.D.</i>  | 23:30           |
| Monitoring Response and Progression in Myeloma<br><i>Shaji Kumar, M.D.</i>  | 23:31           |
| Initial Therapy of Myeloma: Transplant-ineligible Patients<br><i>Morie Gertz, M.D.</i>                                    | 39:56           |
| Benefits of Maintenance Therapy and the Treatment of the First Relapse:<br>A Second Change<br><i>Rafael Fonseca, M.D.</i> | 28:07           |

|  |       |
|--|-------|
| Multiple Myeloma: Late Relapse<br><i>Keith Stewart, M.B, Ch.B.</i>   | 24:56 |
| CLL/Myeloma Diagnosis and Disease Monitoring<br><i>Victoria Alegria, APRN</i>  | 29:21 |
| Hematologic Drugs and Toxicities (Lymphoma, ALL, AML)<br><i>Nicole Gannon, P.A.-C.</i>                                   | 24:44 |
| Myeloma and the Heart<br><i>Jeremy Larsen, M.D.</i>  | 20:52 |
| Management of Newly Diagnoses Multiple Myeloma Including<br>Stem Cell Transplantation<br><i>Sikander Ailawadhi, M.D.</i> | 29:19 |
| Bone Health Management in Multiple Myeloma<br><i>Yi L. Hwa, APRN, C.N.P., D.N.P.</i>                                     | 28:16 |

### **Copyright**

Mayo Foundation for Medical Education and Research. All rights reserved. Copyright 2018